Michel Streuli is CEO of the immunotherapy company Foundery Innovations. Previously he was CSO of Pionyr Immunotherapeutics and prior to Pionyr, he held senior research positions at Gilead, Merck, Schering-Plough, and Organon, following a decade on the faculties of the Dana-Farber Cancer Institute and Harvard Medical School. During his 20 years in the pharmaceutical and biotech industry, he has led numerous drug development programs from discovery into early clinical development, with a focus on therapies for cancer, chronic viral, autoimmune, and inflammatory diseases. Michel received his Ph.D. degree from the University of Zurich.